Skip to content

Therapeutic Alliance and Perceived Closeness in MDMA-Assisted Therapy for Social Anxiety Disorder

Joseph M. Diehl, Christina Chwyl, Liliana Kennedy, Jenna Lejeune, Jason B. Luoma

September 11, 2026 preprint DOI: 10.31234/osf.io/tezgw_v1 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Preregistered secondary analysis of an open-label pilot trial Pilot study
Sample size 20
Population Adults with social anxiety disorder (SAD)
Interventions 3 4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT)
Duration Three preparation sessions, two MDMA dosing sessions, and six integration sessions
Measures Agnew Relationship Measure, Inclusion of Other in the Self Scale, Liebowitz Social Anxiety Scale
Topics Anxiety MDMA
Key findings Therapeutic alliance was high after preparation and increased significantly after the first MDMA session, with ceiling effects later. Perceived closeness to the therapist increased significantly during each MDMA session and decreased during the nondrug interval. Greater MDMA-session closeness predicted lower post-treatment social anxiety, including after adjustment for pre-MDMA closeness, and was associated with self-transcendent emotions and connection-related experiences.

Abstract

The therapeutic relationship is considered central to psychedelic-assisted therapy, yet little empirical research has examined how it changes during 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) or relates to acute MDMA experiences and clinical outcomes, particularly for social anxiety disorder (SAD). This preregistered secondary analysis examined therapeutic alliance and perceived closeness during an open-label pilot trial of MDMA-AT for SAD (N = 20; NCT-redacted-for-anonymous-review). Participants completed three preparation sessions, two MDMA dosing sessions, and six integration sessions. Therapeutic alliance and therapist closeness were assessed before and after each MDMA session using the Agnew Relationship Measure and Inclusion of Other in the Self Scale, respectively. Social anxiety severity was assessed with the Liebowitz Social Anxiety Scale at baseline and post-treatment, and self-transcendent experiences were assessed following MDMA sessions. Alliance was high after preparation and increased significantly following the first MDMA session, with evidence of ceiling effects later in treatment. Closeness increased significantly during each MDMA session and decreased during the subsequent nondrug interval. Greater MDMA-session closeness predicted lower post-treatment social anxiety, including after adjustment for corresponding pre-MDMA closeness. Self-transcendent emotions and connection-related experiences were associated with greater MDMA-session closeness, and pre-dosing closeness predicted greater self-transcendent emotions during the subsequent MDMA session. These findings distinguish more stable therapeutic alliance from more dynamic felt interpersonal closeness and suggest that closeness may be a particularly sensitive relational process in MDMA-AT for SAD.

In the evidence

This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.

  • Perceived closeness to the therapist rose during each MDMA session and greater session closeness predicted lower post-treatment social anxiety, including after adjustment for pre-session closeness.

    Synthesized

Comparable studies

Other non-randomized and open-label trials on MDMA, most cited first.

Study Year Design Participants
Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. Adults with chronic, treatment-resistant PTSD 2013 Long-term follow-up of a completed trial n = 19
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. Patients with alcohol use disorder (AUD) following community alcohol detoxification 2021 Open-label safety and tolerability proof-of-concept study n = 14
MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial. Couples in which one partner was diagnosed with PTSD 2020 Pilot study n = 6
Culturally informed research design issues in a study for MDMA-assisted psychotherapy for posttraumatic stress disorder People of color with posttraumatic stress disorder 2019 Phase 2 open-label multisite study
The Consequences of 3,4-Methylenedioxymethamphetamine Induced CYP2D6 Inhibition in Humans Healthy male subjects 2008 Controlled clinical trial n = 15

Explore topics

By condition and practice